LC
ACRS icon

Lindbrook Capital’s Aclaris Therapeutics ACRS Stock Holding History

Lindbrook Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-383
Closed -$402 – 2645
2023
Q4 		$402 Buy
383
+99
+35% +$302 ﹤0.01% 2596
2023
Q3 		$1.95K Buy
284
+250
+735% +$2.14K ﹤0.01% 2140
2023
Q2 		$353 Buy
+34
New +$308 ﹤0.01% 2577
2023
Q1 		– Sell
-208
Closed -$3.28K – 2770
2022
Q4 		$3.28K Sell
208
-31
-13% -$499 ﹤0.01% 2012
2022
Q3 		$4K Buy
239
+31
+15% +$488 ﹤0.01% 1720
2022
Q2 		$3K Hold
208
– – ﹤0.01% 1730
2022
Q1 		$4K Buy
+208
New +$2.84K ﹤0.01% 1662

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lindbrook Capital's ACRS Position: Q1 2024 in Review

Lindbrook Capital sold out of Aclaris Therapeutics (ACRS) in Q1 2024, closing a stake of 383 shares — an estimated $402 sold.

Lindbrook Capital first reported a position in ACRS in Q1 2022 and held it in 7 quarters. The position peaked at $4K in Q3 2022. 98 funds tracked by Wall St. Rank hold ACRS as of Q1 2024.

  • Lindbrook Capital reported no remaining Aclaris Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Lindbrook Capital sold 383 Aclaris Therapeutics shares in Q1 2024, an estimated $402.
  • Lindbrook Capital first reported a position in Aclaris Therapeutics in Q1 2022 and held it in 7 quarters.
  • Lindbrook Capital's Aclaris Therapeutics position peaked at $4K in Q3 2022.
  • 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2024.

Based on Lindbrook Capital's 13F filing for Q1 2024, filed 25 Apr 2024.